leisure time -WSS

leisure time

author：leisure time 2025-09-06 03:53:04 - browse：9

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The Karikó problem: Lessons for funding basic research

WSS

Why you get paid to donate plasma but not blood

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

2023 Nobel Prize in Medicine goes to Karikó and Weissman

15 die by electrocution after transformer explodes in northern India

The Karikó problem: Lessons for funding basic research

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

leisure time

leisure time

focus

Wildfire smoke exposes gaps in outdoor worker protections

2023 Nobel Prize in Medicine goes to Karikó and Weissman

The high cost of giving birth even with insurance

Lawsuit highlights wrinkle for disputes over surprise medical bills

Trump demands the U.S. pay no more for drugs than other countries … again

Johnson & Johnson sues to stop Medicare negotiation

Jerome Adams on the need for new antivirals for Covid

What we owe ALS patients — and why one company fell short

Hollywood unions extend contract negotiations for actors

Nobel honors Karikó and Weissman's enduring partnership

entertainment

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

6 solutions to address cancer drug shortages and others

European officials brace for rough respiratory virus season

Some top drug companies are starting to take action on climate

More hospitals are billing patients as online messages surge

hotspot

Wikipedia

focus

explore